HomeCompareCAKFY vs JNJ

CAKFY vs JNJ: Dividend Comparison 2026

CAKFY yields 4.15% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.9K in total portfolio value· pulled ahead in Year 9
10 years
CAKFY
CAKFY
● Live price
4.15%
Share price
$4.10
Annual div
$0.17
5Y div CAGR
-2.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$408.34
Full CAKFY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CAKFY vs JNJ

📍 JNJ pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAKFYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAKFY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAKFY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAKFY
Annual income on $10K today (after 15% tax)
$352.44/yr
After 10yr DRIP, annual income (after tax)
$347.09/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,638.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAKFY + JNJ for your $10,000?

CAKFY: 50%JNJ: 50%
100% JNJ50/50100% CAKFY
Portfolio after 10yr
$27.8K
Annual income
$2,548.87/yr
Blended yield
9.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CAKFY
No analyst data
Altman Z
4.1
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAKFY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAKFYJNJ
Forward yield4.15%2.13%
Annual dividend / share$0.17$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-2.5%28%
Portfolio after 10y$25.4K$30.3K
Annual income after 10y$408.34$4,689.40
Total dividends collected$4.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAKFY vs JNJ ($10,000, DRIP)

YearCAKFY PortfolioCAKFY Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,104$404.27$10,592$272.30+$512.00CAKFY
2$12,291$409.05$11,289$357.73+$1.0KCAKFY
3$13,564$412.56$12,123$472.89+$1.4KCAKFY
4$14,928$414.86$13,141$629.86+$1.8KCAKFY
5$16,389$416.05$14,408$846.81+$2.0KCAKFY
6$17,952$416.22$16,021$1,151.60+$1.9KCAKFY
7$19,624$415.45$18,122$1,588.22+$1.5KCAKFY
8$21,412$413.82$20,930$2,228.20+$482.00CAKFY
9← crossover$23,322$411.43$24,792$3,191.91$1.5KJNJ
10$25,363$408.34$30,274$4,689.40$4.9KJNJ

CAKFY vs JNJ: Complete Analysis 2026

CAKFYStock

McKesson Europe AG provides logistics and other services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division engages in the wholesale of pharmaceutical and other health care products. This division serves its customers through 90 wholesale branches that supply pharmaceutical products to approximately 40,000 pharmacies and hospitals, as well as operates 70 distribution centers in Europe. The Retail Pharmacy division operates approximately 2,000 owned pharmacies and approximately 8,000 members in its brand partnership program. This division also provides outpatient drug, e-commerce, and home care services primarily in Belgium, Ireland, Italy, and the United Kingdom under the Lloyds Pharmacy brand. In addition, this division provides traditional prescription drugs, over-the-counter products, and medical services. It also provides other services for pharmacists, such as the organization and management of pharmacy cooperation programs in the Great Britain, France, Portugal, and Belgium. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG is a subsidiary of McKesson Corporation.

Full CAKFY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CAKFY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAKFY vs SCHDCAKFY vs JEPICAKFY vs OCAKFY vs KOCAKFY vs MAINCAKFY vs ABBVCAKFY vs MRKCAKFY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.